The PhD candidate will develop a new analysis framework that will make possible a better understanding of the underlying biology of cell subpopulations in heterogenic tissues and comparison across experimental conditions. The ideal candidate would have a background in bioinformatics, programming, and functional genomics.
Host: BioBam Bioinformatics, Spain.
Supervisor: Stefan Götz (https://www.biobam.com/about/?cn-reloaded=1).
Envisioned secondments: Università degli Studi di Firenze (Italy, 2 months), Josep Carreras Leukaemia Research Institute (Spain, 2 months).
About the INTERCEPT-MDS network
The INTERCEPT-MDS network will train Europe’s first experts in the novel field of disease interception. Through an international call and open recruitment procedure, we will recruit 12 PhD candidates to carry out specific projects under the supervision of a Principal Investigator within one of the 10 world-leading European host institutions from the network. Our future fellows will be enrolled in a PhD programme and will receive an outstanding and tailored training designed specifically for them. In addition to the training offered by the university, supervisors and host institutions, the PhD candidates will also carry out secondments in other European institutions within the network to provide the needed interactions to achieve research and training excellence, and improve the future career perspectives of our PhD fellows. The embedding within the INTERCEPT-MDS network’s experts and experienced trainers from two sectors (academia and industry) and two research environments (clinical and basic) offers a unique multidisciplinary and multisectoral training opportunity in the emerging field of disease interception within the health sciences. Offer Description The Innovative Training Network (ITN) “INTERCEPT-MDS - Exploring cell-to-cell heterogeneity and exploiting epigenetic regulation for the interception of myeloid disease cells" is recruiting 12 highly motivated PhD candidates. The offered positions are available with a duration of 36 months. The fellowships are funded as part of the Marie Skłodowska-Curie Actions (MSCA) Innovative Training Networks under the European Commission’s Horizon 2020 programme. MARIE CURIE GRANT AGREEMENT NUMBER: 953407.
Scientific project Disease interception is a novel concept referring to the treatment of a disease before it fully develops by removing altered cells. To make disease cell interception a reality, researchers need to overcome two key challenges: First, to identify a few altered disease cells among many healthy ones. Second, the development of strategies that allow the specific targeting of malignant cells without affecting healthy cells. INTERCEPT-MDS will approach these challenges using myeloid diseases as a suitable paradigm for clonally evolving diseases and several innovative research tools, aiming at improving the diagnostics and treatment of haematological malignancies and other cancers. The highly complementary composition of the INTERCEPT-MDS network will provide all the key expertise and infrastructure to support the scientific excellence of our PhD candidates, and the transfer of knowledge is guaranteed through shared training.
Application and selection process
The application will be done through an online application platform to be found on the INTERCEPT-MDS website: www.intercept-mds.eu
Based on your current searches we recommend the following search filters.
Check out our other PhDs in Cancer / Oncology
Start a new search with our database of over 4,000 PhDs
Based on your current search criteria we thought you might be interested in these.
Big-data for nano-electronics: high-throughput spectroscopy and imaging for functional nanotechnology development in the presence of disorder
The University of Manchester
Development of a software for real-time analysis and visualisation of big-data for Industry 4.0
University of Sheffield
The development of Rab27 inhibitors for treatment of cancer cell invasion and proliferation
University of Nottingham